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Abstract 
 
  Background: Many multi-valent vaccines target only a subset of all pathogenic types. If 
vaccine and non-vaccine types compete, vaccination may lead to type replacement. The 
plausibility of type replacement has been assessed using the odds ratio (OR) of co-infections in 
cross-sectional prevalence data, with OR > 1 being interpreted as low risk of type replacement. The 
usefulness of the OR as a predictor for type replacement is debated, as it lacks a theoretical 
justification, and there is no framework explaining under which assumptions the OR predicts type 
replacement. 
 Methods: We investigate the values that the OR can take based on deterministic 
Susceptible-Infected-Susceptible and Susceptible-Infected-Recovered-Susceptible multi-type 
transmission models. We consider different mechanisms of type interactions, and explore 
parameter values ranging from synergistic to competitive interactions. 
 Results: We find that OR > 1 might mask competition because of confounding due to 
unobserved common risk factors and cross-immunity, as indicated by earlier studies. We prove 
mathematically that unobserved common risk factors lead to an elevation of the OR, and present an 
intuitive explanation why cross-immunity increases the OR. We find that OR < 1 is predictive for 
type replacement in the absence of immunity. With immunity, OR < 1 remains predictive under 
biologically reasonable assumptions of unidirectional interactions during infection, and an 
absence of immunity-induced synergism. 
 Conclusions: Using the OR in cross-sectional data to predict type replacement is justified, 
but is only unambiguous under strict assumptions. An accurate prediction of type replacement 
requires pathogen-specific knowledge on common risk factors and cross-immunity. 
 
Keywords: pathogen types; interactions; multivalent vaccines; type replacement; cross-sectional 
prevalence; odds ratio; confounding 
  
Introduction 
 Studying and predicting the effects of vaccination against pathogens with many types can 
be challenging if the types interact with each other.
1
 With a vaccine that immunizes against only a 
subset of pathogen types, vaccination may indirectly affect the types that are not targeted. 
Vaccination against the vaccine types may increase or decrease the prevalence of the non-vaccine 
types, depending on whether the interactions between the vaccine and non-vaccine types are 
competitive or synergistic. If the interactions are synergistic, vaccination may decrease the 
prevalence of the non-vaccine types since it also takes away the synergistic effects that the 
non-vaccine types receive from the vaccine types. If the interactions are competitive, vaccination 
may increase the prevalence of the non-vaccine types so that the non-vaccine types replace the 
vaccine types.
2-4
 Such replacements have been observed after the introduction of vaccination 
against pathogens like Haemophilus influenzae and Streptococcus pneumoniae.
5-7
 For human 
papillomavirus (HPV), it is still unclear if different genotypes interact and whether vaccination 
will lead to type replacement.
8,9
 
To assess the risk of type replacement before the introduction of vaccination, investigators 
have searched for evidence of competition between the vaccine and non-vaccine types in 
epidemiologic studies. We focus on cross-sectional prevalence studies that provide information on 
patterns of co-occurrence of pathogen types. Co-occurrence can be defined as co-infection by 
different virus types (e.g. for HPV) or as co-carriage of different bacterial types (e.g. for S. 
pneumoniae), depending on the application. Once the meaning of co-occurrence is defined, type 
interactions can be quantified by the observed number of co-occurrences. Deviations of this 
quantity from the expected number of co-occurrences under independence can be interpreted as 
evidence for interactions. A common measure of association that expresses the extent of such 
deviation is the odds ratio (OR ) of co-occurrence, with positive (negative) associations being 
considered indicative of synergistic (competitive) interactions. 
Although this qualitative interpretation of associations has an intuitive appeal, it may not 
be consistent with the underlying mechanisms of interactions, leading to incorrect assessment of 
the risk of type replacement. While some competitive mechanisms induce negative associations, 
others, such as cross-immunity, have been shown to induce positive associations.
10,11
 Even if the 
underlying mechanism of interactions agrees with this intuitive interpretation, type interactions 
may be confounded by unobserved risk factors or routes of transmission that are shared by 
multiple types, leading to a bias toward positive associations.
8,11,12
 
For HPV, various cross-sectional prevalence studies from the pre-vaccination era found 
co-infections to occur more often than expected, expressing positive associations, but few 
noteworthy differences between type-specific associations are reported.
13-15
 Such co-infection 
patterns are usually explained in terms of unobserved common risk factors, with low risk of type 
replacement according to the intuitive interpretation. However, it is not clear to what extent 
competitive interactions may be masked by common risk factors, and therefore whether type 
replacement following HPV vaccination is plausible. Moreover, it remains to be demonstrated 
whether unobserved common risk factors have the same effect on each type-specific association, 
and can be corrected for. 
Although the validity of using the OR  of co-occurrence for inferring type interactions has 
been studied before,
10,11,16
 its methodologic basis is not yet well established. In this paper, we 1) 
derive the OR  as an estimator of interactions in acquisition and clearance; 2) present a proof for 
positive bias due to unobserved common risk factors; and 3) provide a novel explanation how 
cross-immunity induces positive associations. Ultimately, our goal is to assess the usefulness of 
co-occurrence patterns of pathogen types in cross-sectional prevalence data for predicting type 
replacement.  
  
The OR as an estimator of the interaction parameters  
  
A Susceptible-I nfected-Susceptible model with two pathogen types 
 We first consider a Susceptible-I nfected-Susceptible (SIS) model with two pathogen types 
in a closed population (fig:SIS_structureA).
3,17
 In this population, individuals are susceptible or 
infected with respect to each of the two types so that there are 22 =4 different infection states. We 
encode each of the infection states by a notation in which the i-th letter indicates the status with 
respect to the i-th type: S  for susceptible and I  for infected. In formulae, each of { , , , }SS IS SI II  
denotes the proportion of individuals in the corresponding state in the population. Together, they 
give the joint distribution of the two types. 
In this model, individuals without any infections, the susceptibles, become infected by type 
1 at rate 
1 1= ( )c IS II    and by type 2 at rate 2 2= ( )c SI II   , where c is the contact rate and i  the 
probability of acquiring type i  given established contact with an infected individual. 
  
Types interact through two mechanisms: acquisition and clearance. Due to interactions in 
acquisition, individuals already infected by one type acquire an infection of the other type at an 
adjusted rate that is k  times 
1  or 2 . The interaction parameter k  is essentially the rate ratio of 
acquiring infections of one type among individuals that are already infected by the other type 
(exposed) compared to the acquisition among susceptibles (unexposed). Similarly, due to 
interactions in clearance, individuals that are infected by both types clear infections at an adjusted 
rate that is h  times the clearance rate of individuals that are infected by only one type, 
1  or 2 . 
The interaction parameter h  is therefore the rate ratio of clearing infections of one type among 
individuals infected by the other type (exposed) compared to the clearance among individuals not 
infected by the other type (unexposed). Interactions in acquisition (clearance) can be either 
independent, synergistic, or competitive by choosing k  to be =,>, or < 1 (
1
h
 to be =, >, or < 1) as 
given by Table 1.  
The following system of differential equations describes how { , , , }SS IS SI II  changes over 
time:  
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The stationary distribution 
 { , , , }SS IS SI II , as governed by (1), always stabilizes at an equilibrium as time progresses. 
This occurs for any given set of model parameters. We assume that the model parameters are 
chosen such that both types are present (coexisting) at the equilibrium. 
Equilibria in the deterministic setting are closely related to stationary distributions in 
Markov processes, since both are stable in time. In this paper, we consider the setting in which a 
cross-sectional dataset consists of individuals sampled from a stationary distribution that coincides 
with the equilibrium of the system described by (1). 
As we are interested in the cross-sectional setting, we focus on the equilibrium and neglect 
transient dynamics of { , , , }SS IS SI II . By solving the linear system that governs the equilibrium (see 
eAppendix A), we obtain the following simple expression in terms of 
1 2 1 2{ , , , , , }k h    :  
 1 2
2 1
1 2
1 2
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= ( ) /
= ( ) /
= ( ) / ,
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 where 
1 2 2 1 1 2 1 2=C h h h k         is the normalizing constant. Note that the derivation of (2) 
does not depend on how 
i  is defined in terms of the contact rate and transmission probabilities so 
that (2) holds as long as the model has the structure depicted in Figure 1A. 
 
Result I: The OR is an exact estimator of the composite of the interaction 
parameters, 
k
h
. 
 The OR  is defined as the ratio of the odds of one type in presence of the other type, 
relative to the odds of this type in absence of the other type:  
 =( ) / ( )
II IS
OR
SI SS
 (3) 
 To compute the OR , (2) is substituted in (3). This substitution yields =
k
OR
h
, a function of the 
composite of the interaction parameters. If only one mechanism of interactions is operating, i.e. 
=1h  or =1k , the OR  reduces to k  or the reciprocal of h  as shown in Figure 2A and Figure 2B, 
respectively. An alternative proof of =
k
OR
h
 based on reversibility can be found in eAppendix A. 
The OR as a predictor for type replacement 
  
The outcome of vaccination 
 We investigate whether the OR  correctly predicts the outcome of vaccination. We 
introduce the following indicator function to denote the outcome of vaccinating against type 2 
(vaccine type) for the prevalence of type 1 (non-vaccine type):  
 
 

 

o
, if the prevalence of type1 decreases,
= ,if the prevalence of type1 stays unchanged,
,if the prevalence of type1 increases;type replacement.
 
 Hence, =  denotes a beneficial (and =  an unfavorable) impact on the non-vaccine type due 
to vaccination against the vaccine type. We simulate vaccination by reducing the probability of 
acquiring type 2 throughout the entire population and investigate whether >,=,<1OR  correctly 
predicts = , ,  o , respectively. 
  
In the simulations, different parameter values of k  and h , ranging from competitive to 
synergistic interactions, lead to different outcomes of vaccination Table 2. If one mechanism of 
interactions is independent ( =1k  or 
1
=1
h
),   is determined by the parameter value of the other 
mechanism of interactions with respect to 1. If both mechanisms of interactions are operating, we 
found the outcome of vaccination to be determined by the value of 
k
h
 with respect to 1. As such, 
with both mechanisms operating in opposite directions, one being competitive and the other 
synergistic, the outcome of vaccination is determined by the strongest of the two (i.e. the 
parameter that deviates the most from 1). 
Result II: The OR is a predictor for type replacement. 
 As =
k
OR
h
 and the value of 
k
h
 with respect to 1 determines the value of  , the OR  is a 
predictor for the outcome of vaccination; >,=,<1OR  predicts = , ,  o , respectively. This 
correspondence justifies the intuitive interpretation of the OR . 
If the assumptions of the model are violated, the OR  may no longer be a predictor for the 
outcome of vaccination. In case the interactions are not symmetric among types, the OR  becomes 
a weighted average of the type-specific interaction parameters. If the vaccine type is competitive 
towards the non-vaccine type, but the non-vaccine type is synergistic towards the vaccine type, 
>1OR  may hold even though type replacement does occur. Nevertheless, in less extreme cases of 
asymmetry, e.g. if the vaccine and non-vaccine type are both competitive or both synergistic 
towards each other but with different strength, the OR  still correctly predicts the outcome of 
vaccination. 
 
Positive bias due to unobserved common risk factors 
 Individuals may differ in risk of infections because of differences in genetic disposition or 
behavior. Some risk factors are common for all pathogen types. If a common risk factor is not 
observed nor adjusted for, it may confound the previous result of the OR  being an estimator of 
k
h
 
and a predictor for type replacement. Using an example with unobserved heterogeneity in 
susceptibility, we illustrate the confounding effect due to unobserved common risk factors and 
explain why the bias is towards positive associations. 
 
Heterogeneity in susceptibility 
 We consider a heterogeneous S usceptible- I nected-S usceptible model in which each 
individual is assigned an unobserved susceptibility level z , which influences his/her susceptibility 
for both types. The variation of z  in the population is captured by the density function ( )f z . 
As this model comprises an extra dimension, z , the proportions of different infection states 
at the equilibrium become functions of z : { ( ), ( ), ( ), ( )}SS z IS z SI z II z . To be consistent with the 
notations of the previous model, we let { , , , }SS IS SI II  be the proportions of all individuals in the 
corresponding infection states regardless of the value of z , i.e. for = , , ,A SS IS SI II:  
 
0
= ( )A A z dz

  (4) 
 
We assume homogeneous mixing between individuals with different susceptibility levels. 
To model transmission, we define the global force of infection as 
1 1= ( )c IS II    and 
2 2= ( )c SI II   . We then define the individual-specific force of infection to be the product of the 
individual-specific multiplier, z , and the global force of infection: 
1z  and 2z . In 
fig:SIS_structureB, the infection dynamics of the population with susceptibility level z  is shown. 
The corresponding system of differential equations can be found in eAppendix B. 
 
The crude and the adjusted OR 
 If the susceptibility level is not observed, the crude OR  is computed without 
distinguishing between individuals with different susceptibility levels:  
 =( ) / ( )
II IS
OR
SI SS
 (5) 
 
For the hypothetical situation in which we could observe the susceptibility level, we define 
the adjusted OR  to be the OR  evaluated at each z :  
 
( ) ( )
( ) =( ) / ( )
( ) ( )
II z IS z
OR z
SI z SS z
 (6) 
 
For each fixed susceptible level, z , the corresponding system of differential equations 
follows the same structure as the one of the homogeneous Susceptible-I nected-Susceptible model, 
where 
i  in (1) is replaced by iz . Hence, for each z , the adjusted OR  remains an estimator of 
k
h
. 
  
Result III: The crude OR over-estimates the composite of interaction 
parameters, 
k
h
, and is not a sensitive predictor for type replacement. 
 The crude OR  has a bias towards positive associations: >
k
OR
h
 (see Figure 2A and Figure 
2B). The proof of >
k
OR
h
 in the case of independent interactions 
1
( = =1)k
h
 can be found in 
eAppendix B. The proof invokes Chebyshev’s integral inequality,18 which formalizes a sufficient 
condition for a positive bias. In this example of heterogeneity in susceptibility, this condition 
requires the marginal probability of being infected to be either increasing or decreasing with z  for 
both types. This condition is satisfied since the higher the susceptibility level, the higher the 
probability of being infected. 
Since the crude OR  over-estimates 
k
h
, >1OR  does not necessarily correspond to =  . 
However, <1OR  still corresponds to = . In other words, >1OR  cannot rule out the possibility of 
type replacement, but <1OR  can predict it. 
Using =1OR  as a threshold to distinguish between the presence and absence of type 
replacement leads to an incorrect prediction. However, there is no other threshold value for the OR  
that can produce a correct prediction, since the value of the OR  at = o also depends on the 
chosen model parameters such as 
i  and i . Figure 3 shows the varying value of the OR  under 
independence for different combinations of 
1 2,   (on the left) and 1 2,   (on the right). This 
dependency on type-specific parameters suggests that different type-to-type combinations may 
require different adjustments for the same unobserved common risk factors. 
Unobserved heterogeneity in other variables, that are either negatively or positively 
correlated with being infected with respect to both types, also leads to a positive bias of the OR  for 
k
h
. For instance, heterogeneity in contact rate or clearance rate also lead to an over-estimation of 
k
h
, since the sufficient condition for positive bias we propose is satisfied. With assortative mixing 
according to such a common risk factor, we expect an even stronger positive bias.
19
 
Different forms of bias due to type-specific or cross-immunity 
 The results obtained under the Susceptible-I nected-Susceptible model may not hold if 
natural infections trigger immune responses that protect the host against future infections. In 
general, immunity can be type-specific or cross-protective. For HPV, the strength of naturally 
acquired immunity is still a topic of discussion as is the possibility of cross-protection to related 
genotypes.
20
 For S. pneumoniae, naturally acquired immunity is thought to build up with age and 
likely plays a minor role in transmission dynamics among toddlers, but might mask competition 
among adults.
21
 
In this section, we analyze how type-specific immunity and cross-immunity affect the 
estimation of interaction parameters and the prediction of type replacement. We study the two S
-usceptible-I nfected-R-ecovered-Susceptible (SIRS) models depicted by Figure 4A and Figure 4B. 
The corresponding systems of differential equations can be found in eAppendix C. In both models, 
we incorporate type-specific immunity by expanding the infection dynamics to SIRS with regard 
to each type, where state R (for Recovered) represents the immune state. The number of infection 
states now becomes 23 =9. Individuals enter state R after clearance of infection and exit due to 
waning of immunity at rate 
i  for type i . After losing immunity, individuals return to state S . In 
the SIRS model given by fig:SIRS_structureA, we keep the “SI ”-part of the infection dynamics the 
same as in the previous SIS model, including how types interact in acquisition and clearance. 
Hence, current infections of one type affect susceptibility for and clearance of the other type. In the 
SIRS model given by fig:SIRS_structureB, we let past infections of one type affect susceptibility 
for and clearance of the other type. Such a mechanism of interactions is called indirect, since 
current infections of one type indirectly, through recovery, affect the other type. Indirect 
interactions, if competitive, correspond to cross-immunity, in which case being immune for one 
type offers protection to the other type. We consider direct and indirect interactions in separate 
models, since they lead to qualitatively different kinds of bias. 
After incorporating the immune state, the definition of the OR  as given under result I 
becomes:  
 =( )/ ( )
II IS IR
OR
SI RI SS SR RS RR

   
 (7) 
 This definition matches the empirical setting where one cannot distinguish between 
susceptible and immune individuals. 
 
Result IV: With type-specific immunity, the OR is a biased estimator of 
the composite of the interaction parameters, 
k
h
. 
 In the SIRS  model with direct interactions (Figure 4A), the OR  remains an unbiased 
estimator of 
1
h
, but not of k  unless =1k  (see Figure 2A and Figure 2B). =1OR  still constitutes a 
valid boundary between synergy and competition, however, the OR  over-estimates k  if <1k  and 
under-estimates k  if >1k . Jointly, the OR  becomes biased for 
k
h
 (see eAppendix C for the proof). 
 
Result V: With cross-immunity, the correspondence between the OR and 
the composite of the interaction parameters, 
k
h
, is reversed. 
 In the SIRS model with indirect interactions (Figure 4B), we consider cross-immunity as a 
composite of competition in both acquisition and clearance: past infections of one type hinder the 
acquisition and accelerate the clearance of the other type. We found that parameter values 
corresponding to cross-immunity ( <1k  and 
1
<1
h
) induce positive associations ( >1)OR . Conversely, 
the opposite outcome of negative associations ( <1)OR  holds if interactions are synergistic ( >1k  
and 
1
>1
h
). Hence, the correspondence between the OR  and 
k
h
 is reversed (Figure 2A and Figure 
2B). 
We can understand this reversion by juxtaposing the two SIRS models. In both models, the 
OR  is computed using the same definition, with in the numerator (N): { , , , }SS SR RS RR  and { }II , and 
in the denominator (D): { , }IS IR  and { , }SI RI . In the direct SIRS model, interactions in acquisition 
affect the transitions from states in (D) to states in (N), which is reversed in the indirect SIRS 
model. Correspondingly, in the direct SIRS model, increasing k  increases the flow from states in 
(D) to states in (N) and leads to an increase in the OR  (Figure 2A dotted line), whereas in the 
indirect SIRS  model, increasing k  leads to a decrease in the OR  (Figure 2A, dashed line). 
Analogously, increasing 
1
h
 leads to an increase in the OR  in the direct SIRS model (Figure 2B, 
dotted line) and a decrease in the OR  in the indirect SIRS model (Figure 2B, dashed line). Given 
that =1OR  at 
1
= =1k
h
, inducing cross-immunity by decreasing k  and 
1
h
 from 1 leads to >1OR . 
Predicting type replacement in presence of immunity 
 In the indirect SIRS  model, the OR  is not predictive for type replacement due to the 
reversed correspondence between the OR  and 
k
h
. In the direct SIRS models, if both mechanisms of 
interactions are operating in the same direction, i.e. either 
1
>1, >1k
h
 or 
1
<1, <1k
h
, the outcome of 
vaccination is also still determined by the value of 
k
h
 with respect to 1. For more complicated 
situations in which the two mechanisms of interactions operate in opposite directions, i.e. either 
1
<1, >1k
h
 or 
1
>1, <1k
h
, the outcome of vaccination also depends on the type-specific parameters. 
For example, if current infections of one type increases the susceptibility for the other type 
(synergy, >1k ) but accelerate clearance of the other type (competition, 
1
<1
h
), the outcome of 
vaccination may be =  while >1OR , masking type replacement. In Figure 5, this discrepancy is 
shown by the differences between the -map and the OR-map in the upper left and the lower right 
quadrants. 
 
Discussion 
 In this paper, we studied the usefulness of co-occurrence patterns of pathogen types in 
cross-sectional prevalence data for predicting type replacement. We confirmed the OR  of 
co-occurrence as an estimator of interactions in acquisition and clearance in models, either SIS or 
SIRS, with direct interactions. This correspondence between the OR  and the interactions is reversed 
in the setting of a SIRS model with indirect interactions, that is, when natural immunity against one 
type modifies the infection dynamics of another type. 
We found that >1OR  can be caused by various mechanisms, namely direct synergistic 
interactions, cross-immunity or confounding due to unobserved common risk factors. As >1OR  
can be caused by cross-immunity, it cannot preclude type replacement. On the other hand, we 
confirm <1OR  being predictive for type replacement in the setting without immunity, even under 
confounding by unobserved common risk factors. With immunity, it is predictive for type 
replacement only if 1) different mechanisms of interactions do not act in different directions; and 
2) natural immunity against the vaccine types does not promote infections of the non-vaccine 
types. Such immunity-induced synergism is rare, but has been reported for different strains of the 
dengue virus in the form of antibody-dependent enhancement.
22
 
The conditions, identified by our models, under which <1OR  is predictive for type 
replacement may not be generalizable if we depart from the model assumptions we considered. For 
instance, the predictive power of <1OR  for type replacement may disappear under asymmetric 
interactions among types. Although mild asymmetry (e.g. if one type experiences stronger 
competition from another type than vice versa), may retain the predictive power, more extreme 
asymmetry (e.g. if one type is synergistic towards another type from which it experiences 
competition) may not. Furthermore, we did not consider within-host competition for transmission, 
which affects the transmission capacity in co-infected relative to singly infected individuals. In 
addition, natural immunity may result in a mix of direct and indirect interactions, different than in 
the SIRS models considered here, further complicating the interpretation of the OR . 
Other model assumptions on contact patterns and transmission may lead to different 
interpretation for the OR . For example, the Susceptible-I nected-Recovered-Susceptible model of 
Malagon et al. allows simultaneous acquisition when susceptibles are partnered with co-infected 
individuals.
11
 Their model yields >1OR  even if the type interactions are independent, in contrast to 
our SIRS  models, which find =1OR . This bias of the OR  under independence arises because 
simultaneous acquisition is itself a mechanism that enhances the co-occurrence of types. 
We assumed cross-sectional prevalence data to be sampled from an epidemiologic 
equilibrium in which a stable prevalence of infections is maintained. This stationary assumption is 
reasonable in the pre-vaccination era for endemic pathogens, like S. pneumoniae and HPV, and is 
commonly assumed in transmission modelling.
23
 After the introduction of vaccination, this 
assumption is violated until the prevalence has re-established at a new equilibrium. When the 
prevalence oscillates through the years but has a seasonal pattern, other statistical methods using 
time series to infer type interactions might be more suitable.
22
. Furthermore, individuals reach the 
stationary distribution only after being at risk for some time in practice. The time required to 
achieve stationary depends on the speed of the transmission process and may differ between 
pathogens. 
For HPV, there have been many studies on pre-vaccination cross-sectional data that used 
the OR  to infer competitive interactions.
13-15
 These studies usually adjust for possible unobserved 
common risk factors by either including person-specific random effects or by comparing each 
type-to-type OR  to the pooled OR . After adjustment, most studies find >1OR  or fail to find 
systematic deviations of the type-to-type OR ’s from the pooled OR . However, conclusions 
concerning type replacement should be drawn cautiously in view of alternative explanations for 
these findings, including cross-immunity between types, which entails a risk of type replacement. 
Furthermore, adjustment for unobserved common risk factors need not be similar among types. 
Essentially, previous models account for unobserved risk factors by assuming a random effect that 
is the same for all pairs of types. Our results show that random effects could be different for each 
type-to-type OR . Whether or not such differences among type-to-type combinations are practically 
negligible depends on the application. If not, one may resolve to random effects models that also 
account for differences between types.
24
 
HPV vaccines have demonstrated to be cross-protective for some non-vaccine HPV types 
that are phylogenetically related to the vaccine types.
25-28
 Such cross-protection may substitute the 
competitive pressure by the vaccine types on the non-vaccine types and counterbalance type 
replacement. Including cross-protection would alter the outcome of vaccination in our analyses. 
For some scenarios with <1OR  calculated from the pre-vaccination prevalence, type replacement 
may be mitigated or even prevented by cross-protection if cross-protective efficacy is strong 
enough. Consequently, while <1OR  predicts the potential for type replacement, type replacement 
need not occur in the presence of vaccine cross-protection. 
For other pathogens, it is less common to use the OR  of co-occurrence in a cross-sectional 
setting to study type replacement. We only know of Bogaert et al., who studied the possibility of 
Staphylococcus aureus replacing S. pneumoniae after the introduction of PCV-7.
29
 For S. 
pneumoniae serotypes, we know of no studies on patterns of co-occurrence in the setting we 
discuss before PCV-7 was introduced. 
We note that our models predict a stable equilibrium frequency distribution of 50% 50%  
when applied to epidemiologically indistinguishable types. Hence, they are not neutral from a 
population-genetic point of view as described by Lipsitch et al., who argued that non-neutral 
models are unsatisfactory in explaining the long-term coexistence of types when the evidence for 
competition is compelling.
30
 Thereupon, various neutral models have been suggested, all 
assuming a form of competition, for example, by limiting the number of types that a host can carry 
or by inducing homologous immunity. Yet, a neutral model that intrinsically assumes competition 
may not be appropriate for developing the framework to test for signs of competition, since it has 
no natural representation for the absence of competition, in contrast to our ecologically 
non-neutral models. Furthermore, a stable coexistence of 50% 50%  frequency is not a problem if 
one assumes types that are independent of each other. Even if types are epidemiologically 
indistinguishable (e.g. if they share the same transmission route and have similar infection cycles), 
it is reasonable that they converge to the same frequency if they are not interfering with each other 
during infection or transmission. 
  
So far, only a few studies have commented on the validity of using the OR  of 
co-occurrence to predict type replacement. This study is the first to provide conditions under 
which the OR  is an estimator of interactions and under which it is predictive for type replacement. 
Furthermore, our contribution provides analytical proofs and intuition for earlier findings, such as 
the manifestation of unobserved confounding and the reversed relationship between the OR  and 
type replacement due to cross-immunity. 
Type replacement following vaccination may have detrimental impact on public health. 
Prediction of type replacement based on the OR  of co-occurrence in cross-sectional studies has an 
intuitive appeal, which is mathematically grounded. However, when knowledge of the underlying 
mechanisms of interactions and the structure of confounding is lacking, observed patterns of 
co-occurrence allow for various explanations. Hence, the settings in which the OR  unambiguously 
indicates the possibility of type replacement is narrowed down to pathogens in endemic 
equilibrium, with a well understood infection cycle and natural immunity. As such, to assess 
vaccination effects on the prevalence of non-vaccine types, post-vaccine surveillance studies 
remain essential because potential pitfalls in predicting type replacement are pervasive. 
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Figure  1: The structure of two SIS models for two pathogen types with interactions in acquisition 
and clearance indicated by dashed arrows. We encode each of the infection states by a notation 
in which the i -th letter indicates the status with respect to the i -th type: S for susceptible and 
I  for infected. The susceptibility is assumed to be homogeneous in A and heterogeneous in B. 
B depicts only the subpopulation with susceptibility level z . 
Figure  2: The crude OR  as an estimator of the interaction parameter for acquisition (k ) in A and 
the reciprocal of the interaction parameter for clearance (
1
h
) in B. Homogeneous SIS model 
(solid): unbiased estimation. Heterogeneous SIS model (dashed-dotted): over-estimation. SIRS 
model with direct interactions (dotted): over-estimation of <1k  and under-estimation of >1k , 
unbiased estimation of h (overlapped by the solid line). SIRS model with indirect interactions 
(dashed): reversion bias. 
Figure  3: The crude OR  under independence in the heterogeneous SIS model depends on 
type-specific parameters. A: it varies as 
1  and 2  vary, while 1 2= =1   in A. B: it varies as 1  
and 
2  vary, while 1 2
4
= =
7
  . For both A and B, = 3c  and ( )f z  is a discrete distribution with 
20%-80% mass at = 0.2z  and =1.8z , respectively. 
 
Figure  4: The structure of two SIRS models for two pathogen types with direct interactions in A 
and indirect interactions in B indicated by the dotted arrows. The transition rates not affected 
by type interactions are omitted. The dark gray areas indicate the terms in the numerator (N) of 
the OR , whereas the light gray areas indicate the terms in the denominator (D) of the OR , where 
( ) ( )
= =
( ) ( ) ( )
II SS SR RS RR N
OR
SI RI IS IR D
   
  
. 
 
Figure  5: The outcome of vaccination and the OR  agree when both mechanisms of interactions 
operate in the same direction (the upper right and lower left quadrants), but may differ when 
the two mechanisms operate in different directions (the upper left and lower right quadrants). 
=  ( )  denotes the (non-)occurrence of type replacement by the non-vaccine type. The line 
=1
k
h
 depicts the boundary between =  and =  in the homogeneous SIS model. 
  
Table 1: Parameter values for interaction parameter k  and h  corresponding synergistic, 
independent, and competitive interactions. 
   
 synergy independence competition 
acquisition >1k  =1k  <1k  
clearance 1 >1
h
 
1
=1
h
 
1
<1
h
 
 
  
Table 2: Parameter values for the interaction parameters k  and h  corresponding = , ,  o . 
   
 =  = o =  
Independent in clearance  >1k  =1k  <1k  
Independent in acquisition  1 >1
h
 
1
=1
h
 
1
<1
h
 
Both operating  >1
k
h
 =1
k
h
 <1
k
h
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eAppendix A The homogeneous SIS model
A.1 The linear system at the equilibrium
The equilibrium of the homogeneous SIS model in terms of {λ1, λ2, µ1, µ2, k, h} can be
obtained by solving the following linear system.
0
0
0
0
 =

−(λ1 + λ2) µ1 µ2 0
λ1 −(µ1 + kλ2) 0 hµ2
λ2 0 −(µ2 + kλ1) hµ1
0 kλ2 kλ1 −h(µ1 + µ2)


SS
IS
SI
II
 (1)
A.2 An alternative proof of result I
To better understand how the OR reduces to k
h
, we provide an alternative proof for result I
using the reversibility of the model. A model is reversible if the net ﬂow between any pair
of states is zero, i.e. for any state A and state B, the ﬂow from A to B equals the ﬂow from
B back to A. The ﬂow from A to B is given by the prevalence in A times the transition
rate from A to B, so that we have the following detailed balance equation:
A · qA→B = B · qB→A (2)
Checking the detailed balance equation for each pair of states in our model veriﬁes its
reversibility at the equilibrium. For example, the ﬂow from SS to IS equals the ﬂow from
IS back to SS, i.e.
SS · qSS→IS = hµ1µ2λ1
C
= IS · qIS→SS (3)
This detailed balance property links the prevalence of states, which appear in the deﬁ-
nition of OR, to the interaction parameters, which appear in the deﬁnition of the transition
rates, so that we have:
OR =
II
SI
/
IS
SS
=
qSI→II
qII→SI
/
qSS→IS
qIS→SS
=
kλ1
hµ1
/
λ1
µ1
=
k
h
(4)
The ﬁrst equality of (4) shows that the OR is a ratio between two ratios, II
SI
and IS
SS
.
The second equality evokes the reversibility, which translates these two ratios to ratios of
transition rates between {II, SI} and between {IS, SS}. These transition rates then reduce
to k
h
according to the deﬁnitions. The reversibility is key to the correspondence OR = k
h
,
since the rest of the derivation follows according to the deﬁnitions.
1
eAppendix B The heterogeneous SIS model
B.1 The system of diﬀerential equations
dSS(z,t)
dt
= −(zλ1 + zλ2)SS(z, t) + µ1IS(z, t) + µ2SI(z, t)
dIS(z,t)
dt
= zλ1SS(z, t)− (µ1 + kzλ2)IS(z, t) + hµ2II(z, t)
dSI(z,t)
dt
= zλ2SS(z, t)− (µ2 + kzλ1)SI(z, t) + hµ1II(z, t)
dII(z,t)
dt
= kzλ2IS(z, t) + kzλ1SI(z, t)− h(µ1 + µ2)II(z, t)
(5)
B.2 The proof of OR > 1 under independence
Here, we prove that the crude OR is greater than 1 if the interactions are independent
(k = h = 1) at the equilibrium. Equivalently, we prove that the observed-to-expected ratio
is greater the 1, i.e. II > (IS + II)(SI + II). Let f(z) be the density function of the
susceptibility level so that
∫∞
0
f(z)dz = 1. For notational convenience, we also deﬁne the
following normalized quantities for each z:
piII(z) = II(z)/f(z)
piI∗(z) =
(
IS(z) + II(z)
)
/f(z)
pi∗I(z) =
(
SI(z) + II(z)
)
/f(z)
To verify II > (IS + II)(SI + II), we expand the two sides of the inequality. The left
hand side can be written as
II =
∫ ∞
0
II(z)dz
=
∫ ∞
0
piII(z)f(z)dz
=
∫ ∞
0
piI∗(z)pi∗I(z)f(z)dz
=
(∫ ∞
0
f(z)dz
)(∫ ∞
0
piI∗(z)pi∗I(z)f(z)dz
)
(6)
The third equality is true, since for each value of z the corresponding system of diﬀerential
equations follows the same structure as one of the homogeneous SIS, but with λi being
substituted by zλi (compare the system of ODE of the homogeneous SIS model and (5)).
In the homogeneous SIS model, OR = 1 at k = h = 1. Hence, for each z, OR(z) = 1
at k = h = 1. Equivalently, piII(z) = piI∗(z)pi∗I . Lastly, the fourth equality holds, as∫∞
0
f(z)dz = 1.
The right hand side can be written as
(IS + II)(SI + II) =
(∫ ∞
0
IS(z) + II(z)dz
)(∫ ∞
0
SI(z) + II(z)dz
)
=
(∫ ∞
0
pi1(z)f(z)dz
)(∫ ∞
0
pi2(z)f(z)dz
)
(7)
2
AIS(z)
SS(z)
II(z)
SI(z)
λ1
zµ1
λ2
zµ2
kλ2
hzµ2
kλ1
hzµ1
Heterogeneous clearance rate
B
IS(z)
SS(z)
II(z)
SI(z)
zβ1I1
µ1
zβ2I2
µ2
kzβ2I2
hµ2
kzβ1I1
hµ1
Heterogeneous contact rate
eFigure 1: The structure of two heterogeneous SIS models for two pathogen types with
interactions in acquisition and clearance indicated by dashed arrows. The clearance rate
and contact rate are assumed to be heterogeneous in A and B, respectively. Ii denotes the
proportion of individuals infected by type i throughout the whole population.
We have now arrived at the setting in which we can apply the weighted version of Cheby-
shev's integral inequality. This inequality says that for any continuous function f(z) > 0
on [b, c], and continuous functions pi1(z) and pi2(z) on [b, c] that are both increasing or both
decreasing, the following holds:( c∫
b
f(z)dz
)( c∫
b
pi1(z)pi2(z)f(z)dz
)
>
( c∫
b
pi1(z)f(z)dz
)( c∫
b
pi2(z)f(z)dz
)
(8)
The last step is to prove that pi1(z) and pi2(z) are both increasing in z. For each z, pii(z) at
the equilibrium satisﬁes zλi(1− pii(z)) = µipii(z), which can be rewritten as pii(z) = zλi(zλi+µi) .
As pii(z) has a strictly positive derivative, i.e.
dpii(z)
dz
= λiµi
(zλi+µi)2
> 0, pii(z) is increasing.
Again, in the same manner, heterogeneity in contact rate as given in eFigure 1A also
yields pi1(z) and pi2(z) that are increasing in z. Since at the equilibrium pii(z) satisﬁes
zβiIi(1− pii(z)) = µipii(z), where z is now the varying contact rate and Ii is the proportion
of individuals infected by type i. This equation can be rewritten as pii(z) =
zβiIi
(zβiIi+µi)
. Ii has
the same value for all z at the equilibrium. As pii(z) has a strictly negative derivative, i.e.
dpii(z)
dz
= βiIiµi
(zβiIi+µi)2
> 0, pii(z) is increasing.
At last, heterogeneity in clearance as given in eFigure 1B rate yields pi1(z) and pi2(z)
that are decreasing in z. Since at the equilibrium pii(z) satisﬁes λi(1 − pii(z)) = zµipii(z),
which can be rewritten as pii(z) =
λi
(λi+zµi)
. As pii(z) has a strictly negative derivative, i.e.
dpii(z)
dz
= −λiµi
(λi+zµi)2
< 0, pii(z) is decreasing.
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eAppendix C The SIRS models
C.1 Force of infection{
λ1 = cβ1(IS + II + IR)
λ2 = cβ2(SI + II +RI)
(9)
C.2 Direct interactions
dSS
dt
= −(λ1 + λ2)SS + γ1RS + γ2SR
dIS
dt
= λ1SS − (µ1 + kλ2)IS + γ2IR
dSI
dt
= λ2SS − (µ2 + kλ1)SI + γ1RI
dII
dt
= λ2IS + kλ1SI − h(µ1 + µ2)II
dRS
dt
= µ1IS − (λ2 + γ1)RS + γ2RR
dSR
dt
= µ2SI − (λ1 + γ2)SR + γ1RR
dRI
dt
= hµ1II + λ2RS − (µ2 + γ1)RI
dIR
dt
= hµ2II + λ1SR− (µ1 + γ2)IR
dRR
dt
= µ2RI + µ1IR− (γ1 + γ2)RR
(10)
C.3 Indirect interactions
dSS
dt
= −(λ1 + λ2)SS + γ1RS + γ2SR
dIS
dt
= λ1SS − (µ1 + λ2)IS + γ2IR
dSI
dt
= λ2SS − (µ2 + λ1)SI + γ1RI
dII
dt
= λ2IS + λ1SI − (µ1 + µ2)II
dRS
dt
= µ1IS − (kλ2 + γ1)RS + γ2RR
dSR
dt
= µ2SI − (kλ1 + γ2)SR + γ1RR
dRI
dt
= µ1II + kλ2RS − (hµ2 + γ1)RI
dIR
dt
= µ2II + kλ1SR− (hµ1 + γ2)IR
dRR
dt
= hµ2RI + hµ1IR− (γ1 + γ2)RR
(11)
C.4 The proof of result IV
We show that the OR is an unbiased estimator of 1
h
when there are only interactions in
clearance, but is biased for interactions in acquisition. Together, the OR becomes a biased
estimator of k
h
.
If types interact only through direct interactions in clearance, OR = 1
h
still holds due
to a form of reversibility between {SS, SR,RS,RR}, {II},{SI,RI} and {IS, IR}. These
four groups of states (as indicated by the four grey areas in Figure 4) coincide with the four
factors appearing in the deﬁnition of the OR.
4
The result OR = 1
h
can be derived in a similar way as (4). The corresponding detailed
balanced equations are
(SS + SR) · qSS→IS = (IS + IR) · qIS→RS
SI · qSI→II = II · qII→RI
(12)
Each equation of (9) corresponds to a pair of groups and describes the ﬂow between them.
For instance, the ﬁrst equation corresponds to the pair {SS, SR,RS,RR} and {IS, IR}.
Note that state RS and state RR do not appear in the equation, since they do not have
direct transitions to {IS, IR}. Note also that SS · qSS→IS + SR · qSR→IR is written as
(SS + SR) · qSS→IS, since qSS→IS and qSR→IR are both equal to λ1.
Furthermore, the following proportionality holds:
SI · p = SI +RI
(SS + SR) · p = SS + SR +RS +RR (13)
(10) links SI and SS + SR, which appear in the detailed balanced equations in (9), to
SI +RI and SS +RS + SR+RR, which appear in the deﬁnition of the OR. Hence, using
(9) and (10), the derivation of OR = 1
h
goes as follows:
OR =
II
SI · p/
IS + IR
(SS + SR) · p
=
II
SI
/
IS + IR
SS + SR
=
qSI→II
qII→RI
/
qSS→IS
qIS→RS
=
λ1
hµ1
/
λ1
µ1
=
1
h
(14)
If types only interact through direct interactions in acquisition, the OR becomes a biased
estimator of k unless k = 1. OR = 1 still constitutes a valid boundary between synergy and
competition, however, the OR over-estimates k if k < 1, and under-estimates k if k > 1.
The bias arises as the reversibility breaks down for k 6= 1. The reversibility is violated, since
qSS→IS = λ1 and qSR→IR = kλ1, disrupting the proportionality in (10) so that the derivation
of (11) no longer holds.
Since the OR is biased for k, it is also biased for the composite of the interaction param-
eters, k
h
.
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eAppendix D Computing codes
In Python 3.
import numpy as np
from scipy.integrate import odeint
import matplotlib.pyplot as plt
from matplotlib.patches import Rectangle
# Define the systems of differential equations SIS (homogeneous), SIRSdirect, SIRSindirect, SIS_inhomogeneous
def SIS(state, t, c, beta1, beta2, mu1, mu2, gamma1, gamma2, k1, k2, h1, h2):
SS = state[0]
IS = state[1]
SI = state[2]
II = state[3]
lambda1 = c*beta1*(IS + II)
lambda2 = c*beta2*(SI + II)
dSS = -(lambda1 + lambda2)*SS + mu1*IS + mu2*SI
dIS = lambda1*SS - mu1*IS - k1*lambda2*IS + h1*mu2*II
dSI = lambda2*SS - mu2*SI - k2*lambda1*SI + h2*mu1*II
dII = k1*lambda2*IS + k2*lambda1*SI - (h2*mu1 + h1*mu2)*II
return [dSS, dIS, dSI, dII]
def SIRSdirect(state, t, c, beta1, beta2, mu1, mu2, gamma1, gamma2, k, h, m):
k1, k2, h1, h2 = k, k, h, h
# direct interactions
SS = state[0]
IS = state[1]
SI = state[2]
II = state[3]
RS = state[4]
SR = state[5]
RI = state[6]
IR = state[7]
RR = state[8]
lambda1 = c*beta1*(IS + II + IR)
lambda2 = c*beta2*(SI + II + RI)
dSS = - (lambda1 + lambda2)*SS + gamma2*SR + gamma1*RS
dIS = - (k1*lambda2 + mu1)*IS + lambda1*SS + gamma2*IR
dSI = - (k2*lambda1 + mu2)*SI + lambda2*SS + gamma1*RI
dII = - (h2*mu1 + h1*mu2)*II + k1*lambda2*IS + k2*lambda1*SI
dRS = - lambda2*RS + mu1*IS + gamma2*RR - gamma1*RS
dSR = - lambda1*SR + mu2*SI + gamma1*RR - gamma2*SR
dRI = - mu2*RI + h2*mu1*II + lambda2*RS - gamma1*RI
dIR = - mu1*IR + h1*mu2*II + lambda1*SR - gamma2*IR
dRR = mu1*IR + mu2*RI - (gamma1+gamma2)*RR
return[dSS, dIS, dSI, dII, dRS, dSR, dRI, dIR, dRR]
def SIRSindirect(state, t, c, beta1, beta2, mu1, mu2, gamma1, gamma2, k, h, m):
k1, k2, h1, h2 = k, k, h, h
# indirect interactions (competition -> cross-immunity)
SS = state[0]
IS = state[1]
SI = state[2]
II = state[3]
RS = state[4]
SR = state[5]
RI = state[6]
IR = state[7]
RR = state[8]
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lambda1 = c*beta1*(IS + II + IR)
lambda2 = c*beta2*(SI + II + RI)
dSS = - (lambda1 + lambda2)*SS + gamma2*SR + gamma1*RS
dIS = - (lambda2 + mu1)*IS + lambda1*SS + gamma2*IR
dSI = - (lambda1 + mu2)*SI + lambda2*SS + gamma1*RI
dII = - (mu1 + mu2)*II + lambda2*IS + lambda1*SI
dRS = - (k1*lambda2)*RS + mu1*IS + gamma2*RR - gamma1*RS
dSR = - (k2*lambda1)*SR + mu2*SI + gamma1*RR - gamma2*SR
dRI = - (h1*mu2)*RI + mu1*II + k1*lambda2*RS - gamma1*RI
dIR = - (h2*mu1)*IR + mu2*II + k2*lambda1*SR - gamma2*IR
dRR = h2*mu1*IR + h1*mu2*RI - (gamma1+gamma2)*RR
return[dSS, dIS, dSI, dII, dRS, dSR, dRI, dIR, dRR]
def SIS_heterogeneous(state, t, beta1, beta2, mu1, mu2, k1, k2, z_cup, z_tilde, N_cup, N_tilde):
S_cup = state[0]
S_tilde = state[1]
I1_cup = state[2]
I1_tilde = state[3]
I2_cup = state[4]
I2_tilde = state[5]
I12_cup = state[6]
I12_tilde = state[7]
E1_cup = I1_cup + I12_cup
E2_cup = I2_cup + I12_cup
E1_tilde = I1_tilde + I12_tilde
E2_tilde = I2_tilde + I12_tilde
l1 = beta1 * (E1_cup + E1_tilde)
l2 = beta2 * (E2_cup + E2_tilde)
dS_cup = - z_cup * (l1 + l2) * S_cup + mu1 * (N_cup - S_cup - E2_cup) + mu2 * (N_cup - S_cup - E1_cup)
dE1_cup = - mu1 * E1_cup + z_cup * l1 * S_cup + k2 * z_cup * l1 * (N_cup - S_cup - E1_cup)
dE2_cup = - mu2 * E2_cup + z_cup * l2 * S_cup + k1 * z_cup * l2 * (N_cup - S_cup - E2_cup)
dI12_cup = dE1_cup + dE2_cup + dS_cup
dI1_cup = dE1_cup - dI12_cup
dI2_cup = dE2_cup - dI12_cup
dS_tilde = - z_tilde * (l1 + l2) * S_tilde + mu1 * (N_tilde - S_tilde - E2_tilde) + mu2 * (N_tilde - S_tilde - E1_tilde)
dE1_tilde = - mu1 * E1_tilde + z_tilde * l1 * S_tilde + k2 * z_tilde * l1 * (N_tilde - S_tilde - E1_tilde)
dE2_tilde = - mu2 * E2_tilde + z_tilde * l2 * S_tilde + k1 * z_tilde * l2 * (N_tilde - S_tilde - E2_tilde)
dI12_tilde = dE1_tilde + dE2_tilde + dS_tilde
dI1_tilde = dE1_tilde - dI12_tilde
dI2_tilde = dE2_tilde - dI12_tilde
return [dS_cup, dS_tilde, dI1_cup, dI1_tilde, dI2_cup, dI2_tilde, dI12_cup, dI12_tilde]
# Get the equilibrium of a model with parameters: c, beta1, beta2, mu1, mu2, gamma1, gamma2, k1, k2, h1, h2
def equilibrium(plot, model, num_states, c, beta1, beta2, mu1, mu2, gamma1, gamma2, k1, k2, h1, h2):
# Initialize joint distribution
state0 = [1 / num_states] * num_states
parameters = (c, beta1, beta2, mu1, mu2, gamma1, gamma2, k1, k2, h1, h2)
# Set simulation length and step size
t_0, t_e, t_step = 0, 1000, 0.10
t = np.arange(t_0, t_e, t_step)
# Simulate
state = odeint(model, state0, t, args=parameters)
# Plot the population dynamics in time
if plot:
E1 = []
E2 = []
if num_states == 4:
[S, I1, I2, I12] = state
E1 = I1 + I12
E2 = I2 + I12
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else:
[SS, IS, SI, II, RS, SR, RI, IR, RR] = state
E1 = IS + II + IR
E2 = SI + II + RI
plt.figure()
plt.ylim((0, 1))
title = r'$k = {}, h = {}$'.format(k1, h1)
plt.title(title, fontsize=15)
plt.xlabel('t')
plt.plot(t, E1, '-', color='red', label=r'$E_1$')
plt.plot(t, E2, '-', color='blue', label=r'$E_2$')
plt.legend()
return state[-1,:]
# Plot the outcome of vaccination (Phi)
def plot_k_h_Phi_map(plot, model, num_states, c, beta1, beta2, mu1, mu2, gamma1, gamma2):
num_step, start, end = 30, 0.1, 2.5
parameters = np.linspace(start, end, num_step) # candidate values for the interaction parameter k and 1/h
x = np.repeat(parameters, num_step) # argument x for the Phi-map
y = np.tile(parameters, num_step) # argument y for the Phi-map
z1 = ["yellow"] * (num_step ** 2) # argument c for the Phi-map
z2 = ["yellow"] * (num_step ** 2) # argument c for the or-map
for i in range(num_step**2):
k1, k2 = x[i], x[i]
h1, h2 = 1 / y[i], 1 / y[i]
# k1, k2 = x[i], y[i]
# h1, h2 = 1, 1
eps = 0.000001
print(i, k1, h1)
# print(i, k1, k2)
prevalenceNVT = [0, 0] # prevalenceNVT[0] = post, prevalenceNVT[1] = pre
for l in range(len(beta2)):
betaNVT = beta1
betaVT = beta2[l] # beta of the VT, l=0 pre-vaccination, l=1 post-vaccination
# Simulate the equilibrium
eq = equilibrium(plot, model, num_states, c, betaNVT, betaVT, mu1, mu2, gamma1, gamma2, k1, k2, h1, h2)
odds_ratio = 0
if num_states == 4:
[s, i1, i2, i12] = eq
prevalenceNVT[l] = i1 + i12 # state is + state ii
if prevalenceNVT[l] > eps:
odds_ratio = (s * i12) / (i1 * i2)
else:
[ss, is_, si, ii, rs, sr, ri, ir, rr] = eq
prevalenceNVT[l] = is_ + ii + ir # state is + state ii + state ir
if prevalenceNVT[l] > eps:
odds_ratio = ((ss + rs + sr + rr) * ii) / ((is_ + ir) * (si + ri))
# Compute the odds ratio in the pre-vaccination era
if odds_ratio != 0 and odds_ratio < 1:
z2[i] = "red"
elif odds_ratio != 0 and odds_ratio > 1:
z2[i] = "green"
# Compute the outcome of vaccination Phi
if prevalenceNVT[0] < eps and prevalenceNVT[1] < eps :
z1[i] = "yellow"
elif prevalenceNVT[0] + eps > prevalenceNVT[1]:
z1[i] = "red"
elif prevalenceNVT[0] - eps < prevalenceNVT[1]:
z1[i] = "green"
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else:
z1[i] = "blue"
# Plot Phi-map
# red: Phi = -
# green: Phi = +
# yellow: Phi = na, NVT goes extinct in both the pre- and post-vaccination era
# blue: Phi = o
plt.figure()
plt.scatter(x, y, s=40, c=z1, alpha=1)
plt.xlim(0, x[-1] + (end - start)/num_step)
plt.ylim(0, y[-1] + (end - start)/num_step)
plt.xlabel(r"$k$", size=28, position=(0.9, 0.1))
plt.ylabel(r"$1/h$", size=28, position=(0.1, 0.7))
class_colours = ['red', 'green', 'blue', 'yellow']
class_names = [r'$-$', r'$+$', r'$o$', 'na']
recs = []
for i in range(0, len(class_colours)):
recs.append(Rectangle((0, 0), 1, 1, fc=class_colours[i], alpha=1))
plt.legend(recs, class_names)
# Plot h=1/k, h=1 and k=1
plt.plot(np.linspace(0, end, 100), 1/np.linspace(0, end, 100), '--', color='black', linewidth=5)
plt.axhline(y=1, linestyle='--', color='black', linewidth=5)
plt.axvline(x=1, linestyle='--', color='black', linewidth=5)
# Save the plot
filename = 'Plot_phi'
plt.savefig('Figure/' + filename + '.png')
# Plot or-map
# red: OR < 1
# green: OR > 1
plt.figure()
plt.scatter(x, y, s=40, c=z2, alpha=1)
plt.xlim(0, x[-1] + (end - start) / num_step)
plt.ylim(0, y[-1] + (end - start) / num_step)
plt.xlabel(r"$k$", size=28, position=(0.9, 0.1))
plt.ylabel(r"$1/h$", size=28, position=(0.1, 0.7))
class_colours = ['red', 'green', 'yellow']
class_names = [r'$OR<1$', r'$OR>1$', 'na']
recs = []
for i in range(0, len(class_colours)):
recs.append(Rectangle((0, 0), 1, 1, fc=class_colours[i], alpha=1))
plt.legend(recs, class_names)
# Plot h=1/k, h=1 and k=1
plt.plot(np.linspace(0, end, 100), 1/np.linspace(0, end, 100), '--', color='black', linewidth=5)
plt.axhline(y=1, linestyle='--', color='black', linewidth=5)
plt.axvline(x=1, linestyle='--', color='black', linewidth=5)
# Initialize parameters
c = 1 # Contact rate
beta1 = 1.2 # Acquisition probability, non-vaccine type
beta2 = 2, 2.5 # Acquisition probability, vaccine type, [0]post- and [1]pre-vaccination era
mu1, mu2 = 1, 1 # Clearance rates
gamma1, gamma2 = 1, 1 # Rate of waning immunity
num_states = 9 # Number of infection states (= 4, 9)
model = SIRSdirect # Model (= SIS, SIRSdirect, SIRSindirect)
plot = False # If True, plot the population dynamics in time,
# where E_i(t) is the prevalence of type i at time i.
# Plot the map for the outcome of vaccination (Phi)
# Type 1 is the non-vaccine type (NVT)
# Type 2 is the vaccine type (VT)
plot_k_h_Phi_map(plot, model, num_states, c, beta1, beta2, mu1, mu2, gamma1, gamma2)
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